62022TJ0037_INF
Judgment of the General Court (Second Chamber) of 1 March 2023 –Romedor Pharma v EUIPO – Perfect Care Distribution (Cerviron)
(Case T‑37/22) (
1
)
(EU trade mark – Invalidity proceedings – EU word mark Cerviron – Non-registered earlier national trade mark CERVIRON – Relative ground for invalidity – Article 8(4) and Article 60(1)(c) of Regulation (EU) 2017/1001)
1.
EU trade mark – Appeals procedure – Action before the EU judicature – Jurisdiction of the General Court – Review of the lawfulness of decisions of the Boards of Appeal – Re-examination of the facts in the light of evidence not previously submitted before EUIPO bodies – Precluded
(European Parliament and Council Regulation 2017/1001, Arts 72(2) and 95)
(see paragraphs 18, 19, 27)
2.
EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Non-registered mark or another sign used in the course of trade – Conditions – Interpretation in the light of EU law – Assessment by reference to the criteria determined by the national law governing the sign relied on – Verification of the content of national law – Scope
(European Parliament and Council Regulation 2017/1001, Arts 8(4) and 60(1)(c))
(see paragraphs 38, 39, 54)
3.
EU trade mark – Surrender, revocation and invalidity – Invalidity action based on the existence of an earlier national right – Burden of proof
(European Parliament and Council Regulation 2017/1001, Arts 8(4) and 60(1)(c))
(see paragraph 40)
4.
EU trade mark – Surrender, revocation and invalidity – Relative grounds for invalidity – Non-registered mark or another sign used in the course of trade – Word mark Cerviron and non-registered mark CERVIRON
(European Parliament and Council Regulation 2017/1001, Arts 8(4) and 60(1)(c))
(see paragraphs 46, 47, 49-52, 55)
Operative part
The Court:
1.
Dismisses the action;
2.
Orders Romedor Pharma SRL to bear its own costs and to pay those incurred by the European Union Intellectual Property Office (EUIPO);
3.
Orders Perfect Care Distribution SRL to bear its own costs.
(
1
)	OJ C 138, 28.3.2022.